天津医药

• 药物临床观察 • 上一篇    下一篇

不同剂量瑞舒伐他汀对急性冠脉综合征患者血清sOX40L、MMP-9的影响

王林军   

  1. 南京中医药大学附属连云港市中医院
  • 收稿日期:2013-11-15 修回日期:2014-04-23 出版日期:2014-09-15 发布日期:2014-09-15
  • 通讯作者: 王林军

Effects of Serum sOX40L, MMP-9 in Patients with Acute Coronary Syndromes by Rosuvastatin with Different Doses

Lin-Jun WANG   

  1. Department of Cardiology, Lianyungang T.C.M. Hospital Affiliated to Nanjing University of Traditional Chinese Medicine,
  • Received:2013-11-15 Revised:2014-04-23 Published:2014-09-15 Online:2014-09-15
  • Contact: Lin-Jun WANG

PDF (PC)

2713

摘要： 目的　探讨不同剂量瑞舒伐他汀对急性冠脉综合征（ACS）患者血清可溶性OX40配体（sOX40L）、基质金属蛋白酶9（MMP-9）的影响。方法　选择ACS患者60例，空白对照组20例。随机将ACS患者分为20 mg瑞舒伐他汀治疗组（20mg组）30例和10 mg瑞舒伐他汀治疗组（10mg组）30例，比较治疗前后各组间血清sOX40L、MMP-9的水平变化。结果　瑞舒伐他汀治疗2周后，两治疗组患者血清sOX40L、MMP-9水平均较治疗前明显降低，差异有统计学意义（P<0.01）。其中20mg组较10mg组降低更为明显，差异有统计学意义（P<0.05）。 结论　ACS患者早期使用较大剂量瑞舒伐他汀可明显减少冠状动脉粥样斑块基质成分的降解和炎症反应，从而起到稳定动脉粥样硬化斑块，改善ACS患者的预后的作用。

关键词: 斯伐他汀, 冠状动脉疾病, 基质金属蛋白酶9, 可溶性OX40配体

Abstract: [Abstract] Objective To explore effects of serum soluble OX40 ligand (sOX40L), matrix metalloproteinase-9 (MMP-9) in patients with acute coronary syndromes (ACS) by rosuvastatin with different doses. Methods 60 patients with ACS were evenly devided into 20mg rosuvastatin treatment group (20mg group) and 10mg rosuvastatin treatment group (10mg group) at random, and 20 healthy volunteers were randomly assigned to control group. Serum concentrations of sOX40L, MMP-9 among above three groups were measured and analyzed before and after treatment. Results After two weeks’ treatment with rosuvastatin, serum concentrations of sOX40L, MMP-9 in patients of two treatment groups decreased significantly compared with pre-treatment (P<0.01). Moreover, the levels of sOX40L, MMP-9 in patients of 20mg group were lower than those in patients of 10mg group after two weeks’ treatment with rosuvastatin(P<0.05). Conclusion Larger doses of rosuvastatin may decrease the degradation of extraceller matrix of coronary atherosclerotic plaque and inflammatory reaction, stabilize coronary atherosclerotic vulnerable plaque when being used to treat patients with ACS, and can play a important role in improving prognosis of patients with ACS.

Key words: rosuvastatin, acute coronary syndromes, soluble OX40 ligand, matrix metalloproteinase-9